SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2), also known as 2019-nCoV, is a positive-sense single-stranded RNA virus. It caused coronavirus disease in 2019 (COVID-19). SARS-CoV-2 contains glycosylated spike (S) protein, which is composed of S1 subunit and S2 subunit. The S1 contains a receptor-binding domain (RBD) that can bind to ACE2 receptor on target cells. Lineage B.1.351 (a.k.a. 20H/501Y.V2) is a variant of SARS-CoV-2. It has multiple mutations in the RBD, including K417N, E484K, N501Y. Lineage B.1.1.7 (a.k.a. 20I/501Y.V1) is also a variant of SARS-CoV-2 and has a mutation called N501Y in the RBD.SARS-CoV-2 Spike (E484) Neutralizing Antibody (COV2109) is produced from cell culture in vitro under conditions free from animal-derived components. The product is a humanized neutralizing antibody, recognizing E484 site of wild-type RBD. When E484 is mutated to E484K, the mutant RBD, such as RBD (B.1.351) as seen in Figure 1, can’t be recognized by the product.
- High specificity
- High affinity
- High stability
Genscript offers site-specific neutralizing antibodies, neutralizing antibody standards, and control antibodies.
Type:
Antigen: SARS-CoV-2 RBD
Clonality: Monoclonal
Clone: COV2109
Conjugation:
Epitope:
Host: Human
Isotype: IgG1
Reactivity: